NMTRQ (9 Meters Biopharma) EBITDA Margin %: 0.00% (As of Mar. 2023)


What is 9 Meters Biopharma EBITDA Margin %?

9 Meters Biopharma NMTRQ -90.00% EBITDA Margin % is 0.00% as of Mar. 2023.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. 9 Meters Biopharma's EBITDA for the three months ended in Mar. 2023 was $-13.11 Mil. 9 Meters Biopharma's Revenue for the three months ended in Mar. 2023 was $0.00 Mil. Therefore, 9 Meters Biopharma's EBITDA margin for the quarter that ended in Mar. 2023 was 0.00%.

9 Meters Biopharma  (OTCPK:NMTRQ) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

9 Meters Biopharma EBITDA Margin % Related Terms

9 Meters Biopharma EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for 9 Meters Biopharma's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

9 Meters Biopharma EBITDA Margin % Chart

9 Meters Biopharma Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

9 Meters Biopharma Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NMTRQ vs USRM, NOVNQ, ONCSQ: EBITDA Margin % Comparison

For the Biotechnology subindustry, 9 Meters Biopharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

9 Meters Biopharma EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 9 Meters Biopharma's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where 9 Meters Biopharma's EBITDA Margin % falls into.


9 Meters Biopharma EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

9 Meters Biopharma's EBITDA Margin % for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-41.091/0
= %

9 Meters Biopharma's EBITDA Margin % for the quarter that ended in Mar. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2023 )/Revenue (Q: Mar. 2023 )
=-13.114/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
9 Meters Biopharma (NMTRQ) has a EBITDA Margin % of 0.00% as of Mar. 2023. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on 9 Meters Biopharma and its competitors.
Is 9 Meters Biopharma's EBITDA Margin % too high?
9 Meters Biopharma's current EBITDA Margin % is 0.00%.
How does 9 Meters Biopharma's EBITDA Margin % compare to USRM and NOVNQ?
9 Meters Biopharma's EBITDA Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on 9 Meters Biopharma and its competitors. 9 Meters Biopharma's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 9 Meters Biopharma stock overvalued right now?
9 Meters Biopharma (NMTRQ) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For 9 Meters Biopharma (NMTRQ), the current EBITDA Margin % is 0.00% as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

9 Meters Biopharma Business Description

Address 4509 Creedmoor Road, Suite 600, Raleigh, NC, USA, 27612
9 Meters Biopharma Inc is a clinical-stage company pioneering novel treatments for people with rare digestive diseases, gastrointestinal (GI) conditions with unmet needs, and debilitating disorders in which the biology of the gut is a contributing factor. Its pipeline includes vurolenatide, a proprietary Phase 3 long-acting glucagon-like-peptide 1 (GLP-1) agonist for short bowel syndrome (SBS) and a robust pipeline of early-stage candidates for undisclosed rare diseases and/or unmet needs.